InspireMD Q2 net loss widens to $13.2M ($0.26/share); revenue up 2.3% to $1.78M

InspireMD, Inc.

2025-Q2 EPS reported -$0.48 revenue$3,307,000

Net loss of $13.2M ($0.26 per share) vs $7.9M loss ($0.22) in Q2 2024; operating expenses surged 55% to $13.3M.
Revenue of $1.78M, up 2.3% YoY; gross profit fell 5.4% to $313k; cash & securities dropped to $19.4M from $34.6M.
Company raised $58M in gross proceeds from equity private placement and warrant exercise.
FDA granted PMA approval for CGuard Prime carotid stent; US commercial launch commenced; CE Mark under MDR also received.
Appointed Mike Lawless as CFO and added Raymond W. Cohen to Board of Directors.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.